Maxim Group reiterated their buy rating on shares of Mesoblast (NASDAQ:MESO) in a report issued on Tuesday morning, AnalystRatings.com reports.
“Mesoblast announced that the FDA has agreed to a rolling review of the BLA for Remestemcel-L in pediatric steroid-refractory aGvHD. The company intends to begin the submission process soon.”,” the firm’s analyst wrote.
A number of other brokerages have also weighed in on MESO. ValuEngine lowered shares of Mesoblast from a buy rating to a hold rating in a report on Tuesday, December 18th. Zacks Investment Research raised shares of Mesoblast from a hold rating to a strong-buy rating and set a $5.50 price objective on the stock in a report on Wednesday, January 16th. Finally, HC Wainwright reissued a buy rating and set a $6.50 price objective on shares of Mesoblast in a report on Thursday, January 31st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $13.10.
Mesoblast (NASDAQ:MESO) last released its quarterly earnings results on Wednesday, February 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). Mesoblast had a negative return on equity of 15.98% and a negative net margin of 528.80%. The firm had revenue of $1.87 million during the quarter, compared to analysts’ expectations of $6.36 million. On average, sell-side analysts predict that Mesoblast will post -0.92 EPS for the current year.
Institutional investors have recently modified their holdings of the business. OLD Mission Capital LLC acquired a new position in shares of Mesoblast in the fourth quarter worth about $60,000. Jane Street Group LLC acquired a new position in shares of Mesoblast in the third quarter worth about $117,000. Citadel Advisors LLC acquired a new position in shares of Mesoblast in the third quarter worth about $215,000. Penbrook Management LLC raised its position in shares of Mesoblast by 6.2% in the fourth quarter. Penbrook Management LLC now owns 240,900 shares of the company’s stock worth $993,000 after acquiring an additional 14,000 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Mesoblast by 249.8% in the third quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock worth $1,348,000 after acquiring an additional 117,951 shares during the period. Institutional investors and hedge funds own 2.85% of the company’s stock.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Story: How does inflation affect different investments?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.